ZUMA 2 - MCL Tecartus 2. Linie (#1347)
Laufzeit: 01.01.2022 - 31.12.2025
imported
Kurzfassung
A phase 2 multicenter study evaluating the efficacy of KTE-X19 in subjects with relapsed/refractory mantle cell lymphoma (ZUMA-2)
Laufzeit: 01.01.2022 - 31.12.2025
A phase 2 multicenter study evaluating the efficacy of KTE-X19 in subjects with relapsed/refractory mantle cell lymphoma (ZUMA-2)